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Randomized trials provide high-quality evidence for patient
care. The Der Deutsche Diabetes Dialyse Studie (4D), a
randomized study which demonstrated no benefit of statins
among diabetic patients receiving hemodialysis, was
published in July 2005. To determine effects of this study we
conducted a retrospective, population-based, time series
analysis with change-point regression to see if the rate of
statin prescription to dialysis patients had been modified. We
linked health administrative data for all diabetic hemodialysis
patients living in Ontario, Canada, with similar characteristics
to the 4D patient cohort. During the nearly 11-year period
prior to study publication, the rate of statin use increased
almost 14-fold, from 43 to 597 per 1000 patients. For 2.5
years after study publication, rather than diminish, statin use
continued to rise to an absolute rate of 676 per 1000
patients. These temporal patterns in statin use closely
mimicked trends in the diabetic population not receiving
dialysis. The 4D trial had no impact on statin use when we
restricted the analysis to incident statin prescriptions or
expanded the characteristics of the dialysis patients
considered for study. Thus, we found that publication of a
large, expensive, randomized controlled trial in patients
receiving hemodialysis had no immediate impact on clinical
practice. The use of a common cardiovascular medication in
this patient population appears to be influenced by other
factors.
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The goal of clinical research is to improve patient health
through the development of new medical knowledge.
Randomized trials are considered the gold standard for
providing knowledge on the utility, benefits, and harms
of an intervention.1 Studies in the general population
have shown that the publication of a large trial can influence
physician care practices.2–5 For example, there was a
sudden, dramatic increase in the number of prescriptions
for ramipril after the release of the Heart Outcomes
Prevention Evaluation trial, which showed clear benefit
in the secondary prevention of cardiovascular disease.4
Similarly, there was a sudden decline in estrogen replacement
therapy prescribing after publication of the Women’s
Health Initiative, which found health risks associated with
the use of combined estrogen and progestin.3 In both cases,
changes in prescribing occurred within months after trial
publication.
Unfortunately, compared with other disciplines, there is a
paucity of high quality randomized data in patients with
kidney diseases (including those receiving dialysis).6 In
addition, systematic reviews suggest that such patients are
routinely excluded from large cardiovascular trials.7 In the
absence of renal trial data, some nephrologists are accus-
tomed to placing a greater emphasis on other types of
evidence or weighing trial evidence from the general
population to a greater degree. When interventions are
tested in patients with kidney disease only after proving
effective in the general population, discordant results among
trials may leave some physicians puzzled as to what to do. All
of these considerations make the uptake of evidence from
large renal trials uncertain. One of the largest randomized
controlled trials ever published in nephrology is Der
Deutsche Diabetes Dialyse Studie (4D), which showed no
beneficial effect of statins in diabetic patients receiving
hemodialysis.8 We sought to determine whether there was a
change in statin use among diabetic patients on dialysis after
the publication of 4D.
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RESULTS
Baseline characteristics
In September 1994, there were 115 diabetic patients receiving
hemodialysis in Ontario who met the criteria of being similar
to the 4D population. By September 2007, this number had
increased to 595 patients. The number of diabetic patients
not receiving dialysis was 114,263 in 1994 and 242,209 in
2007.
Baseline characteristics are summarized in Table 1. The
mean age for Ontario diabetic patients on hemodialysis in
this study was higher than the mean age for German diabetic
patients on hemodialysis in 4D (73 years vs 66 years old).
This was not surprising given that we excluded patients in
Ontario who were less than 66 years of age to ensure that all
patients were eligible for coverage under the provincial drug
plan. The proportion of women studied was similar.
However, the duration of dialysis was longer and cardiovas-
cular disease was less prevalent in Ontario.
Primary analysis
Before the publication of 4D, from September 1994 to July
2005, the rate of statin use dramatically increased 13.9-fold
from 43 to 597 per 1000 diabetic patients on hemodialysis.
After the publication of 4D, rather than diminishing, statin
use continued to rise to a rate of 676 per 1000 patients by
December 2007. This represented a further 1.1-fold increase
in the rate of statin use. Using regression analysis, the age and
sex standardized rate of statin use per 1000 diabetic
hemodialysis patients increased by 51.2 annually (95%
confidence interval (CI), 50.7–51.9) before 4D. After 4D,
the rate increased by 40.6 per 1000 annually (95% CI, 1.8 to
82.8). The slopes of the lines before and after 4D were not
statistically different. These temporal patterns in statin use
mimicked trends in the comparison group of diabetic
patients not receiving dialysis (Figure 1).
Additional analyses
Der Deutsche Diabetes Dialyse Studie had no impact on
statin use when we restricted the analysis to incident statin
prescriptions, prescriptions written by nephrologists, or
expanded the range of dialysis patients considered. The
results were no different in multiple other sensitivity analyses.
In the year 2007, the annual cost of the statin prescriptions
per 1000 diabetic patients receiving hemodialysis was 490,424
dollars CAD (496,330 dollars US).
DISCUSSION
Despite statin trials in the general population excluding
patients with renal disease, the use of statins in diabetic
patients on hemodialysis in Ontario increased by more than
Table 1 | Characteristics of diabetic hemodialysis patients in
Ontario and in Der Deutsche Diabetes Dialyse Studie (4D)
trial
Ontarioa 4D trialb
Sample size 595 1255
Age, years 73 66
Women, % 45 46
Time receiving dialysis, months 14 8
History of cardiovascular diseasec
Myocardial infarction 9 17
Congestive heart failure 21 35
Means presented for continuous measures and percentages for categorical measures.
aPatient characteristics for Ontario are reported for the last time interval
(1 September 2007 to 31 December 2007).
bWe performed a weighted average of placebo and atorvastatin groups to derive
the patient characteristics of the 4D trial.
cThose with a history of a cardiac event or cardiac intervention in the previous 3
months were excluded from Ontario and the 4D trial. In Ontario, conditions were
assessed with administrative database codes as described in Supplementary
Appendices B and C, using data available in 3 the years before study entry. This
differs from 4D, where conditions were assessed directly from patients and their
medical charts.
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Figure 1 | Statin use in diabetic patients receiving and not receiving hemodialysis.
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13.9-fold over a decade from 1994 to 2005. This dramatic
increase remained evident when only new statin prescriptions
were considered, and when the ordering physician was a
nephrologist. In July 2005, the 4D trial was published in a
high impact journal. To date, 4D has been one of the largest
published randomized controlled trials on the effect of statins
in hemodialysis patients. Contrary to most statin trials in the
general population, this trial failed to show a statistically
significant benefit of atorvastatin in preventing cardiovas-
cular events in diabetic patients on hemodialysis.8 Despite
this negative result, however, this trial had no apparent
impact on prescribing practice in Ontario. The rate of statin
use in diabetic hemodialysis patients continued to increase by
another 1.1-fold over the 2 years after the publication of 4D.
There are several potential explanations as to why
physicians did not reduce their statin prescribing behavior
in response to 4D. First, as shown in Table 2, there were many
clinical studies showing the beneficial effects of statins on
cardiovascular outcomes in other populations.9–17 It is
possible that physicians doubted the results of 4D for various
reasons and placed greater importance on the evidence from
observational studies involving dialysis patients or rando-
mized trials involving the general population. At present,
there are two ongoing large trials assessing the effect of statins
on major cardiovascular events in patients with advanced
renal disease: AURORA18 (A study to evaluate the Use of
Rosuvastatin in subjects On Regular hemodialysis, recruited
2775 patients) and SHARP19 (Study of Heart And Renal
Protection, recruited 9000 patients, simvastatin plus ezeti-
mibe is the regime being tested). Physicians may be waiting
for the completion of these trials before deciding to make a
change to their current clinical practice.
Second, a neutral trial where the results do not show a
statistically significant effect with either a distinct harm or
benefit may be discounted by physicians. As shown with the
Heart Outcomes Prevention Evaluation trial and the
Women’s Health Initiative, trials which show strong evidence
of benefit or harm from a treatment have dramatically
changed prescribing practices.3,4 Although in 4D there was an
increased risk of fatal stroke in the statin treatment group
compared with the placebo group (relative risk of 2.03; 95%
CI, 1.05–3.93; P¼ 0.04),8 the authors suggest that this may
have been a chance finding given the results of the CARDS
(Collaborative Atorvastatin Diabetes Study) trial which
showed that atorvastatin reduced stroke by 48% (95% CI,
11 to 69%).12
Third, despite 4D being a multicentered trial, it was only
conducted in a single country, Germany. It is very possible
that 4D impacted clinical practices in Germany due to local
influential physicians, which did not translate to Canada. If
this is true, then the AURORA and SHARP trials, which are
recruiting patients and engaging investigators in multiple
countries, including Canada, may have a larger global
influence.
Finally, the inertia of previous practice may also be
contributing to the lack of expected response after 4D. A
patient’s cardiovascular and diabetic medication regimen
while on dialysis is strongly influenced by the medications
they were receiving before dialysis, which are frequently
prescribed by physicians other than nephrologists. Nephrol-
ogists may be reluctant to discontinue statin therapy if it was
initiated before dialysis treatment, and particularly if it was
started by another physician. However, in our study, there
was no difference in the results when we restricted the
analysis to incident statin use. Diabetic patients on dialysis
are also likely to have multiple physicians involved in their
ongoing care, including nephrologists, endocrinologists, and
cardiologists. Although the results of the 4D trial may be
familiar to nephrologists, it is possible that other providers
were less familiar or influenced by its results. However, again,
when we restricted the analysis to statins only prescribed by
nephrologists, the results were no different.
Our study has many strengths. It is a large, population-
based assessment of statin use in patients over the age of 65
receiving dialysis over the span of 13 years in Canada’s largest
province. The same methods were used to compare the
results to the general population over the same time period.
We used validated codes and methods to ascertain the patient
population, baseline characteristics, and outcomes. Finally,
we confirmed the findings were robust in a number of
additional analyses. However, there are some limitations to
our study which merit consideration. Although we tried to
model our Ontario patient population to closely match the
population in the 4D trial, we were not able to fully apply the
4D inclusion and exclusion criteria given the limitations of
administrative data; in particular, there was an age difference
between the two samples. Also, it was not possible to evaluate
the extent to which other potential factors, such as
pharmaceutical marketing, influenced prescribing patterns.
In conclusion, the publication of a large, expensive
randomized controlled trial in patients receiving hemodia-
lysis had no apparent effect on clinical practice. Growth in
statin prescribing, both before and after the trial, confirms
the use of common cardiovascular medications in this patient
population is influenced by other factors. It remains to be
seen how other high profile renal trials testing interventions
commonly used in the general population will impact clinical
practice in the future.
MATERIALS AND METHODS
Study design and setting
We conducted a retrospective, population-based, interventional
analysis that used several linked health-care databases in Ontario,
Canada from 1 September 1994 to 31 December 2007. Each year was
divided into three 4-month intervals (January to April, May to
August, and September to December), for a total of 40 consecutive
intervals in the time series. Baseline characteristics were assessed
within the 3 years preceding each interval. Ontario is Canada’s most
populous and ethnically diverse province (38% of the Canadian
population) with more than 12 million residents, of whom 77% are
Caucasian, 51% are female, 1.6 million are 65 years of age or older
(Statistics Canada, 2006 Census), over 800,000 (8.8%) are diabetic,20
and 8677 are receiving dialysis (7127 hemodialysis, 1550 peritoneal
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Table 2 | Key statin publications and guidelines from 1994 to 2007: randomized controlled trials, observational studies, and
clinical practice guidelines
Date
Landmark statin trials with renal exclusion criteria
noted, if any Clinical practice guidelines
November 1994 4S (n=4444): simvastatin was beneficial in patients with MI
for secondary prevention.9
November 1995 WOSCOPS (n=6595): pravastatin was beneficial in patients for
primary prevention of coronary heart disease.17
Excluded ‘creatinine 4155mmol/l’ (41.76mg/dl)29
October 1996 CARE (n=4159): pravastatin was beneficial in patients with MI
for secondary prevention.15
Excluded ‘nephrotic syndrome or other renal disease’30 (2+
proteinuria or greater on routine dipstick testing or serum
creatinine values 41.5 times the upper limit of normal as
defined by the central study laboratory).
May 1998 AFCAPS/TexCAPS (n=6605): lovastatin was beneficial in
patients for primary prevention of acute major coronary
events.13
Excluded ‘nephrotic syndrome’.31
November 1998 LIPID (n=9014): pravastatin was beneficial in patients with
acute coronary syndrome for secondary prevention.10
Excluded ‘renal disease’.32
September 1999 AHA: for patients with diabetes, the primary goal of therapy is to
reduce the LDL-C levels to p100mg/dl (p2.59mmol/l) by
adding drug therapy, when necessary, to maximal dietary
therapy. Statins are first-line therapy to achieve an LDL-C of
p100mg/dl (p2.59mmol/l).33
May 2001 NCEP ATP III Executive Summary: for patients with CHD or CHD
risk equivalents, the LDL goal iso100mg/dl (o2.59mmol/l) and
LDL-lowering drug therapy, usually with a statin, should be
considered when LDL X130mg/dl (X3.36mmol/l).34
January 2002 USRDS Dialysis Morbidity and Mortality Wave II (n=3716):
statins reduced cardiovascular-specific death and total
mortality in dialysis (peritoneal dialysis and hemodialysis)
patients (observational study).35
May 2002 AHA Executive Summary: for patients with diabetic dyslipidemia,
LDL lowering, usually with statins, is the
primary target to achieve an optimal level of p100mg/dl
(p2.59mmol/l).36
July 2002 HPS (n=20,536): simvastatin was beneficial in high-risk
patients for secondary prevention of major vascular events
(mortality and fatal/non-fatal vascular events).11
Excluded ‘severe renal disease or evidence of
impaired renal function (creatinine 42.3mg/dl
(4200mmol/l))’.11
November 2002 PROSPER (n=5804): pravastatin reduced the risk of coronary
disease in elderly patients with a history of, or risk factors for,
vascular disease.37
Excluded patients with ‘serum creatinine 4200mmol/l
(42.3mg/dl)’.38
December 2002 ALLHAT-LLT (n=10,355): pravastatin, compared to usual care,
did not significantly reduce all-cause mortality or combined
fatal and nonfatal CHD in older patients with well-controlled
hypertension and moderately elevated LDL-C.39
NCEP ATP III Final Report: persons with established CHD should
receive intensive LDL-lowering therapy.
Excluded patients with ‘serum creatinine 42mg/dl
(4176.8mmol/l)’.39
The goal of therapy in persons with established CHD should be
LDL cholesterol o100mg/dl (o2.59mmol/l). Statins should be
considered as first-line drugs when LDL-lowering drugs are
indicated to achieve LDL treatment goals.40
January 2003 CARE post hoc subgroup analysis (n=1711): pravastatin is
effective and safe for secondary prevention of cardiovascular
events in persons with mild chronic renal insufficiency
(creatinine clearance p75ml/min (p1.25ml/s) using the
Cockcroft-Gault equation).41
April 2003 ASCOT-LLA (n=10,305): atorvastatin was beneficial in
patients with hypertension in reducing major cardiovascular
events.16
KDOQI: consider treatment for patients with stage 5 CKD and
LDLX100mg/dl (X2.59mmol/l) or fasting TGX200mg/dl
(X2.26mmol/l) and non-HDL cholesterol LDLX130mg/dl
(X3.36mmol/l).42
July 2004 NCEP ATP III: In high-risk persons, the recommended LDL-C goal
is o100mg/dl (o2.59mmol/l). An LDL-C goal of o70mg/dl
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Table 2 | Continued
Date
Landmark statin trials with renal exclusion criteria
noted, if any Clinical practice guidelines
(o1.81mmol/l) is a therapeutic option on the basis of available
clinical trial evidence, especially for patients at very high risk. If
LDL-C is X100mg/dl (X2.59mmol/l), an LDL-lowering drug is
indicated simultaneously with lifestyle changes. If baseline LDL-C
is o100mg/dl (o2.59mmol/l), institution of an LDL-lowering
drug to achieve an LDL-C level o70mg/dl (o1.81mmol/l) is a
therapeutic option on the basis of available clinical trial
evidence.43
August 2004 CARDS (n=2838): atorvastatin was beneficial in patients with
type 2 diabetes for primary prevention of first cardiovascular
disease events, including stroke.12
Excluded ‘severe renal dysfunction or nephrotic syndrome or
creatinine 4150mmol/l’ (41.7mg/dl).44
January 2005 DOPPS (n=7365): statins reduced cardiovascular-specific
mortality and all-cause mortality in hemodialysis patients
(observational study).45
April 2005 TNT (n=10,001): high-dose atorvastatin was beneficial in
patients with stable coronary heart disease for secondary
prevention.14
Excluded ‘nephrotic syndrome’.46
July 2005 4D (n=1255): atorvastatin had no significant effect on the
composite primary end point in patients with diabetes
receiving hemodialysis.8
August 2005 IDF Global Guideline for Type II Diabetes: recommendations for
the standard care of cardiovascular risk protection includes
providing active management of all blood lipid profile and statin
treatment at standard dose for all patients440 years old (or all
with declared cardiovascular disease) or 420 years old with
microalbuminuria or assessed as being at particularly high risk.
(IDF, 2005)
May 2006 CHEP: statin therapy is recommended in hypertensive patients
with 3 or more cardiovascular risk factors.47
September 2006 CCS: for those low- and moderate-risk individuals who are
candidates for statin therapy, treatment to lower LDL-C by at
least 40% is generally appropriate. In high-risk individuals,
treatment should be started immediately and concomitantly
with diet and exercise. The treatment goal for most high-risk
patients is to achieve an LDL-C of less than 77.3mg/dl
(2.0mmol/l); an optimal reduction in LDL-C for most CAD
patients is at least 50%.48
January 2007 AHA/ADA: in individuals with diabetes who are over the age of
40 years, without overt CVD, but with 1 or more major CVD risk
factors, the primary goal is an LDL-C level o100mg/dl
(o2.59mmol/l). If LDL-lowering drugs are used, a reduction of at
least 30% to 40% in LDL-C levels should be obtained. If baseline
LDL-C is o100mg/dl (o2.59mmol/l), statin therapy should be
initiated based on risk factor assessment and clinical judgment.
In individuals with diabetes who are under the age of 40 years,
without overt CVD, but who are estimated to be at increased risk
of CVD either by clinical judgment or by risk calculator, the LDL-
C goal is o100mg/dl (o2.59mmol/l), and LDL-lowering drugs
should be considered if lifestyle changes do not achieve the
goal.49
February 2007 KDOQI: treatment with a statin should not be initiated in
patients with type II diabetes on maintenance hemodialysis who
do not have a specific cardiovascular indication for treatment.21
4D, Der Deutsche Diabetes Dialyse Studie; 4S, Scandinavian Simvastatin Survival Study; AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; AHA,
American Heart Association; ADA, American Diabetes Association; ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial–Lipid-Lowering
Trial; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial, Lipid-Lowering Arm; ATP III, Adult Treatment Panel III; CAD, Coronary Artery Disease; CHD, Coronary Heart
Disease; CARDS, Collaborative Atorvastatin Diabetes Study; CARE, Cholesterol and Recurrent Events; CCS, Canadian Cardiovascular Society; CVD, Cardiovascular Disease; CHEP,
Canadian Hypertension Education Program; DOPPS, Dialysis Outcomes and Practice Patterns Study; HDL, high-density lipoprotein; HPS, Heart Protection Study; IDF,
International Diabetes Federation; KDOQI, Kidney Disease Outcomes Quality Initiative; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LIPID, long-
term intervention with pravastatin in ischemic disease; MI, myocardial infarction; NCEP, National Cholesterol Education Program; PROSPER, Prospective Study of Pravastatin in
the Elderly at Risk; TNT, treating to new targets; USRDS, United States Renal Data System; WOSCOPS, West of Scotland Coronary Prevention Study.
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dialysis) (Canadian Organ Replacement Register, 2005). Emigration
from the province is less than 1% per year (Ontario Ministry of
Finance, Ontario Population Projections Update, 2007). Ontarians
have access to health care and those 65 years of age and older also
have their prescription medications paid for by a universal
government plan. This study was conducted according to a
prespecified protocol, and ethics approval was obtained from the
institutional review board at Sunnybrook Health Sciences Centre
(Toronto, Canada).
Intervention
Der Deutsche Diabetes Dialyse Studie is currently the only
randomized trial to examine the effect of statin use on cardiovas-
cular outcomes in patients receiving maintenance hemodialysis.8
This prospective, multicenter, double-blind trial recruited 1255
German chronic hemodialysis patients with type II diabetes who
were randomized to receive either atorvastatin 20mg/day or
placebo. The trial cost was approximately 24 million CAD dollars
(15 million US dollars, 17 million Euros) (C. Wanner, 2008,
personal communication). The results showed that atorvastatin did
not significantly reduce the primary end point of cardiovascular
death, non-fatal myocardial infarction, or stroke. In a secondary
analysis, there was an unexpected increase in fatal strokes in the
atorvastatin group compared with those receiving placebo. The trial
investigators concluded that ‘in persons with type II diabetes
mellitus who are receiving maintenance hemodialysis and have
low-density lipoprotein cholesterol values between 80 and 190mg
per deciliter (2.07 and 4.92mmol/l), routine treatment with a
statin to reduce the primary end point of death from cardiac
causes, myocardial infarction, and stroke is not warranted.’8 The
results were initially presented at the American Society of
Nephrology (ASN) Annual Meeting in October 2004 and the trial
was published on 21 July 2005 in the New England Journal of
Medicine. In 2007, the American National Kidney Foundation
Kidney Disease Outcomes Quality Initiative (NKF KDOQI) changed
their clinical practice guidelines to recommend that ‘treatment with
a statin should not be initiated in patients with type II diabetes
on maintenance hemodialysis who do not have a specific
cardiovascular indication for treatment.’21 No Canadian guidelines
for dialysis patients were published on this topic. In this study, we
specified the publication date of 4D (21 July 2005) as the primary
time point to assess whether there was a change in prescribing
practice.
Data sources
We determined drug use by accessing the Ontario Drug
Benefit (ODB) administrative database, which records outpatient
prescription claims for all patients older than 65 years. This included
all medications in the statin drug class (Supplementary
Appendix A). To be covered, a prescription medication must be
resupplied at least every 100 days, which is why we used time series
intervals of 4 months. We identified dialysis patients using the
Ontario Health Insurance Plan (OHIP) database. We determined
baseline characteristics of age and gender using the Registered
Persons Database (RPDB). Finally, we determined diagnostic and
procedural information from the Canadian Institute for Health
Information Discharge Abstract Database (CIHI-DAD), which
documents all hospitalizations and includes up to 16 diagnoses
and 25 procedures for each admission. We used database codes with
proven validity as detailed in Supplementary Appendix B. All of
these data source have been successfully used in previous studies to
examine prescribing rates of statins and a number of other
medications in Ontario.3–5,22,23
Population
At the beginning of each 4-month interval, we considered all
diabetic hemodialysis patients living in Ontario, Canada who were
similar to patients recruited into 4D. Eligible patients were restricted
to those aged 66 years and older to allow for the presence of Ontario
drug coverage for at least an entire previous year. As was carried out
in 4D, we excluded patients older than 80 years, as well as those with
a cardiovascular event in the preceding 3 months (namely a hospital
encounter for vascular intervention, congestive heart failure, or
myocardial infarction). Also in keeping with 4D, we excluded those
receiving hemodialysis for more than 2 years. Those receiving
hemodialysis for less than 90 days were also excluded, to eliminate
those who may have received hemodialysis for potentially reversible
acute kidney injury. Finally, we also excluded patients who had
evidence of a renal transplant or peritoneal dialysis in the preceding
3 months. A detailed description of the algorithm used to define
maintenance hemodialysis is provided in Supplementary Appendix
C. An example of how the exclusion criteria were applied for each
interval is provided in Supplementary Appendix D.
Primary analysis
The primary study outcome was the rate of statin prescriptions
filled in each 4-month interval per 1000 patients. Patients who filled
more than one statin prescription in a given interval were only
counted once.
Additional analyses
We conducted several sensitivity analyses to test the robustness of
our results. First, we restricted the analysis to incident statin use by
excluding patients who filled a statin prescription in the preceding
year. Second, we restricted the statin prescriptions to those where
the ordering physician was a nephrologist. Third, we changed the
characteristics of dialysis patients by varying the criteria to include
those without diabetes, those on dialysis for greater than 2 years,
those older than 80 years of age, and those with a cardiovascular
event in the preceding 3 months. Finally, we provided the annual
cost of the statin prescriptions (as paid for by the drug benefit
program for each patient). We did not include any co-payments
made by Ontario residents, which were small in nature.
Comparison group
For comparison, we also examined statin use in diabetic patients in
Ontario who met the same eligibility criteria with the exception that
they were not receiving dialysis. To help interpret secular changes in
statin use, we summarized the publication of 15 landmark statin
trials, as well as the introduction of 11 practice guidelines related to
statin therapy, spanning 1994 to 2007 (Table 2). Guidelines were in
the fields of diabetes, hypertension, cardiovascular disease, and renal
disease.
Statistical analysis
Change-point regression was used to determine whether there was a
difference in the age and sex standardized rate of statin use before
and after 4D.24,25 As data were collected every 4 months, and 4D was
published on 21 July 2005, we defined the change-point as occurring
at the third period of the year beginning 1 September 2005. There
were 33 periods before 4D and 7 periods after. The design matrix is
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described elsewhere.24 The annual increase in statin use and 95% CIs
were estimated using linear regression. We used an F-test to
determine whether there was difference in slope before and after
4D.24 Statistical assumptions for the linear model were met;
specifically, the Durbin–Watson statistic for autocorrelation was
reviewed and auto-correlations and inverse and partial autocorrela-
tions were visually inspected; a first-order autoregressive parameter
was included if the Durbin–Watson test statistic was significant.26,27
Multiple sensitivity analyses were performed: excluding the first 12
observations, examining non-age and sex standardized rates, and
performing the analysis with another model (interventional
autoregressive integrated moving-average (ARIMA) time series
models with a step function).28 Results were considered statistically
significant at the 0.05 level using two-tailed tests. Statistical analyses
were performed using SAS statistical software, version 9.1.3 (SAS
Institute, Cary, NC, USA) and R version 2.6.1, (The R Foundation
for Statistical Computing). Graphs were generated using R version
2.6.1 and PowerPoint 2003 (Microsoft, Redmond, WA, USA).
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